Richard Harris

Award-winning journalist Richard Harris has reported on a wide range of topics in science, medicine and the environment since he joined NPR in 1986. In early 2014, his focus shifted from an emphasis on climate change and the environment to biomedical research.

Harris has traveled to all seven continents for NPR. His reports have originated from Timbuktu, the South Pole, the Galapagos Islands, Beijing during the SARS epidemic, the center of Greenland, the Amazon rain forest, the foot of Mt. Kilimanjaro (for a story about tuberculosis), and Japan to cover the nuclear aftermath of the 2011 tsunami.
In 2010, Harris' reporting revealed that the blown-out BP oil well in the Gulf of Mexico was spewing out far more oil than asserted in the official estimates. That revelation led the federal government to make a more realistic assessment of the extent of the spill.

Harris covered climate change for decades. He reported from the United Nations climate negotiations, starting with the Earth Summit in Rio de Janeiro in 1992, and including Kyoto in 1997 and Copenhagen in 2009. Harris was a major contributor to NPR's award-winning 2007-2008 "Climate Connections" series.

Over the course of his career, Harris has been the recipient of many prestigious awards. Those include the American Geophysical Union's 2013 Presidential Citation for Science and Society. He shared the 2009 National Academy of Sciences Communication Award and was a finalist again in 2011. In 2002, Harris was elected an honorary member of Sigma Xi, the scientific research society. Harris shared a 1995 Peabody Award for investigative reporting on NPR about the tobacco industry. Since 1988, the American Association for the Advancement of Science has honored Harris three times with its science journalism award.

Before joining NPR, Harris was a science writer for the San Francisco Examiner. From 1981 to 1983, Harris was a staff writer at The Tri-Valley Herald in Livermore, California, covering science, technology, and health issues related to the nuclear weapons lab in Livermore. He started his career as an AAAS Mass Media Science Fellow at the now-defunct Washington (DC) Star.

Harris is co-founder of the Washington, D.C., Area Science Writers Association, and is past president of the National Association of Science Writers. He serves on the board of the Council for the Advancement of Science Writing.

A California native, Harris returned to the University of California-Santa Cruz in 2012, to give a commencement address at Crown College, where he had given a valedictory address at his own graduation. He earned a bachelor's degree at the school in biology, with highest honors.

Dr. Jonathan Sevransky was intrigued when he heard that a well-known physician in Virginia had reported remarkable results from a simple treatment for sepsis. Could the leading cause of death in hospitals really be treated with intravenous vitamin C, the vitamin thiamine and doses of steroids?

A study published Monday is pushing back against the notion that up to 40 percent of Americans should be taking statin drugs to reduce the risk of heart disease. The study, in the Annals of Internal Medicine, argues that current medical guidelines haven't adequately considered the risks from these widely used drugs.

The youngest children in a school class are most likely to be diagnosed with attention deficit hyperactivity disorder, when in fact their comparatively fidgety behavior may be due to their relative immaturity, according to a study published online Wednesday.

A startup genetics company says it's now offering to sequence your entire genome at no cost to you. In fact, you would own the data and may even be able to make money off it.

Nebula Genomics, created by the prominent Harvard geneticist George Church and his lab colleagues, seeks to upend the usual way genomic information is owned.

Researchers expect that three dozen new drugs will come on the market over the next few years with astronomical prices — some likely topping a million dollars per patient.

The drugmaker Novartis has told investors it might be able to charge $4 million to $5 million for one of its potential products, a treatment for a rare disease called spinal muscular atrophy.

A treatment for early stage cervical cancer that has rapidly gained acceptance in the United States turns out to be worse than standard surgery, according to two studies.

The practice, now thrown into question, is called minimally invasive surgery. Instruments are threaded through small incisions, and surgeons use those to remove a diseased uterus. This technique has been growing in popularity since 2006 and has been widely adopted.

Powerful drugs that have been used for decades to treat delirium are ineffective for that purpose, according to a study published online Monday in the New England Journal of Medicine.

Antipsychotic medications, such as haloperidol (brand name, Haldol), are widely used in intensive care units, emergency rooms, hospital wards and nursing homes.

Hospitals and health plans are increasingly using the huge amount of medical data they collect for research. It's a business worth billions of dollars, and sometimes those discoveries can be the foundation of new profit-making products and companies.

When a company profits from your data, should you get a cut?

This isn't just a hypothetical question. When Steven Petrow was 26 years old, back in 1984, he was treated for testicular cancer at Memorial Sloan Kettering Cancer Center in New York City.

If you are one of the 5.7 million Americans who ends up in the intensive care unit each year, you are at high risk of developing long-term mental effects like dementia and confusion. These mental problems can be as pronounced as those experienced by people with Alzheimer's disease or a traumatic brain injury and many patients never fully recover.

Doctors have gradually come to realize that people who survive a serious brush with death in the intensive care unit are likely to develop potentially serious problems with their memory and thinking processes.

This dementia, a side effect of intensive medical care, can be permanent. And it affects as many as half of all people who are rushed to the ICU after a medical emergency. Considering that 5.7 million Americans end up in intensive care every year, this is a major problem that until recently, has been poorly appreciated by medical caregivers.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

RACHEL MARTIN, HOST:

This year's Nobel Prize for Physiology or Medicine (ph) will be given to two scientists whose discoveries have led to a revolution in cancer treatment.

(SOUNDBITE OF ARCHIVED RECORDING)

Here's a bold idea to fight back against bacteria that can't be stopped by antibiotics: Go after them with germ-eating microbes. That reasoning lies behind an intriguing line of research that might also be put to use in the event of a germ-warfare attack.

For the fourth year in a row, federal health officials report that there has been a sharp increase in sexually transmitted diseases in the U.S. The Centers for Disease Control and Prevention tallied nearly 2.3 million cases of chlamydia, gonorrhea and syphilis in 2017 — an increase of 200,000 cases over the previous year, and a record high.

A consumer advocacy organization is asking federal health officials Tuesday to halt a large medical study being conducted at major universities nationwide.

Public Citizen says that the study, involving treatment for sepsis, puts patients at risk and will at best produce confusing results.

The world of social science got a rude awakening a few years ago, when researchers concluded that many studies in this area appeared to be deeply flawed. Two-thirds could not be replicated in other labs.

Some of those same researchers now report those problems still frequently crop up, even in the most prestigious scientific journals.

But their study, published Monday in Nature Human Behaviour, also finds that social scientists can actually sniff out the dubious results with remarkable skill.

Federal health advisers say women can now consider three options when it's time for their cervical cancer screening tests. The influential group, the U.S. Preventive Services Task Force, has expanded its recommendations for this potentially lifesaving exam.

The new recommendations are published in the latest issue of JAMA.

Healthy women with normal pregnancies can opt to have labor induced without worrying that the decision will make a cesarean section more likely, according to a major study published in this week's New England Journal of Medicine.

When you go to your doctor's office, sometimes it seems the caregivers spend more time gathering data about you than treating you as a patient.

Electronic medical records are everywhere – annoying to doctors and intrusive to patients.

But now researchers are looking to see if they can plow through the vast amount of data that's gathered in those records, along with insurance billing information, to tease out the bits that could be useful in refining treatments and identifying new uses for drugs.

Most drugs have side effects, but sometimes they're actually good news.

Researchers are now exploring whether some cheap and common drugs have side effects that could help people fight off the flu and other lung infections.

New advances in medicine also tend to come with a hefty dose of hype. Yes, some new cancer drugs in the hot field of precision medicine, which takes into account variables for individual patients, have worked remarkably well for some patients. But while many patients clamor for them, they aren't currently effective for the vast majority of cancers.

One of the enduring mysteries of biology is why so much of the DNA in our chromosomes appears to be simply junk. In fact, about half of the human genome consists of repetitive bits of DNA that cut and paste themselves randomly into our chromosomes, with no obvious purpose.

A study published Thursday finds that some of these snippets may actually play a vital role in the development of embryos.

For many years, the death rate from cancer climbed steadily, and the focus of big cancer meetings was the quest for better treatments to bring malignancies under control. Cancer death rates have been falling in recent decades, and that's allowed researchers to ask another important question: Are some people getting too much treatment for their cancers?

The answer, from the American Society of Clinical Oncology meeting in Chicago these past few days, is an emphatic yes.

If you go to the hospital for medical treatment and scientists there decide to use your medical information to create a commercial product, are you owed anything as part of the bargain?

That's one of the questions that is emerging as researchers and product developers eagerly delve into digital data such as CT scans and electronic medical records, making artificial-intelligence products that are helping doctors to manage information and even to help them diagnose disease.

Artificial intelligence, which is bringing us everything from self-driving cars to personalized ads on the web, is also invading the world of medicine.

In radiology, this technology is increasingly helping doctors in their jobs. A computer program that assists doctors in diagnosing strokes garnered approval from the U.S. Food and Drug Administration earlier this year. Another that helps doctors diagnose broken wrists in X-ray images won FDA approval on May 24.

Updated 12:43 p.m. ET

Perhaps 5,000 people died in Puerto Rico in 2017 for reasons related to September's Hurricane Maria, according to a study that dismisses the official death toll of 64 as "a substantial underestimate."

A research team led by scientists at the Harvard T.H. Chan School of Public Health didn't simply attempt to count dead bodies in the wake of the powerful storm. Instead, they surveyed randomly chosen households and asked the occupants about their experiences.

The Food and Drug Administration has approved a first-of-its-kind drug that reduces the number of migraines among people prone to these sometimes crippling headaches.

Sometimes less may be better when it comes to treatment for breast cancer. A new study finds that women who have been diagnosed with early-stage HER2-positive breast cancer did just as well with six months of treatment with the drug Herceptin (trastuzumab) as did women who received a 12-month course of this treatment.

And the women with the shorter treatment had fewer side-effects, most notably less damage to their hearts.

Children and adolescents are getting fewer prescription drugs than they did in years past, according to a study that looks at a cross-section of the American population.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

ARI SHAPIRO, HOST:

Scientists have launched two large studies to test a medical treatment that, if proven effective, could have an enormous impact on the leading cause of death in American hospitals.

The treatment is aimed at sepsis, a condition in which the body's inflammatory response rages out of control in reaction to an infection, often leading to organ damage or failure. There's no proven cure for sepsis, which strikes well over 1 million Americans a year and kills more than 700 a day.

Pages